Wrist Slap for CEO Who Defrauded USAID out of Hundreds of Millions
Former CEO Derish Wolff of Louis Berger Group, one of the country’s largest engineer contracting firms will be confined to his home for a year and have to pay a $4.5 million fine for helping to defraud the federal government out of hundreds of millions of dollars over 20 years. The fine represents a tiny fraction of the amount the company collected from the government.
Wolff, 70, was sentenced by U.S. District Court Judge Anne Thompson for leading a “conspiracy to defraud USAID by billing the agency on so-called ‘cost-reimbursable’ contracts—including hundreds of millions of dollars of contracts for reconstructive work in Iraq and Afghanistan” and for inflating overhead costs.
Related: U.S. Blew $500k on Melting Afghan Buildings
Federal prosecutors said the company, tasked with building roads and bridges in Afghanistan and Iraq, charged the government 140 percent of the actual cost for every project it did. That means that for every one dollar of work the contractor did, it received $1.40 extra. Louis Berger was paid more than $2 billon by the U.S. government for its infrastructure work in war zones.
Prosecutors said that between 1990 and 2009, Wolff and his colleagues inflated the costs of their work for USAID by telling accountants to “pad time sheets with hours ostensibly devoted to federal government projects when it had not actually worked on such projects.”
Related: Pentagon Won’t Verify $300 Million a Year in Afghanistan is Spent Properly
Beyond logging false work hours, the prosecutor said Wolff routinely instructed his subordinates to bill USAID for all of their overhead expenses—like rent at Louis Berger’s Washington office even though the D.C. office worked on other projects that had nothing to do with the federal government.
After two other company executives pleaded guilty to conspiring to defraud the federal government in 2010, Louis Berger Group agreed to make full restitution to USAID. It settled civil and criminal charges and had to pay $18.7 million in criminal fines and an additional $50.6 million to resolve allegations that it violated the False Claims Act by significantly overbilling USAID.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.